397 related articles for article (PubMed ID: 25048685)
1. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
2. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
3. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
[TBL] [Abstract][Full Text] [Related]
5. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
6. The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers.
Rijken JA; Niemeijer ND; Jonker MA; Eijkelenkamp K; Jansen JC; van Berkel A; Timmers HJLM; Kunst HPM; Bisschop PHLT; Kerstens MN; Dreijerink KMA; van Dooren MF; van der Horst-Schrivers ANA; Hes FJ; Leemans CR; Corssmit EPM; Hensen EF
Clin Genet; 2018 Jan; 93(1):60-66. PubMed ID: 28503760
[TBL] [Abstract][Full Text] [Related]
7. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
[TBL] [Abstract][Full Text] [Related]
8. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
9. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.
Janssen I; Blanchet EM; Adams K; Chen CC; Millo CM; Herscovitch P; Taieb D; Kebebew E; Lehnert H; Fojo AT; Pacak K
Clin Cancer Res; 2015 Sep; 21(17):3888-95. PubMed ID: 25873086
[TBL] [Abstract][Full Text] [Related]
10. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
11. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
[TBL] [Abstract][Full Text] [Related]
13. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.
Timmers HJ; Gimenez-Roqueplo AP; Mannelli M; Pacak K
Endocr Relat Cancer; 2009 Jun; 16(2):391-400. PubMed ID: 19190077
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
16. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
Gupta S; Zhang J; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
[TBL] [Abstract][Full Text] [Related]
17. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
18. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
[TBL] [Abstract][Full Text] [Related]
19. Genetic testing in pheochromocytoma or functional paraganglioma.
Amar L; Bertherat J; Baudin E; Ajzenberg C; Bressac-de Paillerets B; Chabre O; Chamontin B; Delemer B; Giraud S; Murat A; Niccoli-Sire P; Richard S; Rohmer V; Sadoul JL; Strompf L; Schlumberger M; Bertagna X; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
J Clin Oncol; 2005 Dec; 23(34):8812-8. PubMed ID: 16314641
[TBL] [Abstract][Full Text] [Related]
20. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]